Niki BioSolutions director reports 6,024 share stake

Niki BioSolutions, Inc. director Laura A. Philips filed an initial ownership report on Form 3.

Accepted by SEC EDGAR 07/24/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Niki BioSolutions, Inc. director Laura A. Philips filed an initial ownership report on Form 3. On 2026-07-20 she reported direct beneficial ownership of 6,024 shares of Common Stock of Niki BioSolutions. The filing lists this holding as a baseline position and does not report any buy or sell transactions.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Philips Laura A

Role Director

Type	Security	Shares	Price	Value
Holding	Common Stock	--	--	--

Holdings: Common Stock — 6,024 shares (Direct)

Key Figures

Common shares held: 6,024 shares Holding entries reported: 1

2 metrics

Common shares held 6,024 shares Direct holdings of Laura A. Philips reported on Form 3

Holding entries reported 1 Number of non-transactional holding rows in this Form 3

Key Terms

Common Stock, Rule 10b5-1, Direct/Indirect ownership type

3 terms

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Rule 10b5-1 regulatory

"aff_10b5_one is the filing's document-level Rule 10b5-1 checkbox"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Direct/Indirect ownership type financial

"direct_or_indirect uses D/I for Direct/Indirect ownership type"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing for Niki BioSolutions (NIKI) report?

The Form 3 reports that director Laura A. Philips holds 6,024 shares of Niki BioSolutions Common Stock. It is an initial ownership statement and does not disclose any purchase or sale transactions.

How many Niki BioSolutions (NIKI) shares does Laura A. Philips report owning?

Laura A. Philips reports beneficial ownership of 6,024 shares of Niki BioSolutions Common Stock. This figure comes from the total shares following transaction field in the Form 3 holding entry.

Is Laura A. Philips’ reported Niki BioSolutions (NIKI) ownership direct or indirect?

The Form 3 shows her 6,024 shares as direct ownership, using the ownership code "D". No indirect holdings through trusts or other entities are listed in this filing.

Does the Niki BioSolutions (NIKI) Form 3 show any recent insider trades?

No. The Form 3 includes a holding entry with no transaction code and shows 6,024 shares held. The transaction summary records one holding entry and no buy or sell share activity.

Who is the reporting person in the Niki BioSolutions (NIKI) Form 3?

The reporting person is Laura A. Philips, who is identified in the filing as a director of Niki BioSolutions, Inc. She reports direct beneficial ownership of 6,024 Common Stock shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Philips Laura A

(Last) (First) (Middle)

C/O NIKI BIOSOLUTIONS, INC.

116 VILLAGE BOULEVARD, SUITE 200

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/20/2026

3. Issuer Name and Ticker or Trading Symbol
Niki BioSolutions, Inc. [ NIKI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	6,024	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Laura A. Philips	07/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)